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Multiple sclerosis is the most common cause of chronic 
neurological disability in young adults in developed 
countries and seems to be increasing in frequency.1,2 
Disease presentation in 80–90% of patients follows 
an initial phase characterised by bouts of relapsing-
remitting neurological dysfunction.3 These relapses are 
thought to represent focal areas of inﬂ ammation in the 
CNS, and arise with unpredictable frequency and variable 
recovery.4 However, after an inconsistent interval, most 
patients then develop a progressive disease course, with 
a gradual development of disability in the absence of 
relapses. The later disease phase accounts for most of 
the permanent disability and is thought to be mediated 
by neurodegenerative processes including axonal 
degeneration.5 Although some controversy remains 
regarding the rate at which conversion to secondary 
progressive multiple sclerosis takes place, a ﬁ gure of 2–3% 
per year with age-related inﬂ uences is widely accepted.6 
The overall eﬀ ect, in a disorder whose duration exceeds 
30 years, is that most patients will, at some stage, develop 
secondary progressive multiple sclerosis, and at any one 
time most prevalent patients are in a disease phase for 
which there is no eﬀ ective treatment.
Initial therapeutic advances targeted the early 
inﬂ ammatory disease phase, with several licensed 
immunomodulatory treatments emerging. Treatments 
available to clinicians for management of relapsing-
remitting multiple sclerosis are now substantial. 
Available drugs all have an eﬀ ect on relapse frequency, 
reduction of brain MRI lesion formation, and can reduce 
permanent disability when deﬁ ned as worsening with 
no reversal in 3–6 months. However, the pattern of 
rising severity and frequency of serious adverse events 
with increasing drug eﬃ  cacy needs careful patient 
selection, clinical management, and surveillance. Despite 
these limitations, early and eﬀ ective intervention 
for relapsing-remitting multiple sclerosis is hoped to 
have the long-te rm outcome of delaying or abolishing 
the progressive phase. Nevertheless, evidence for 
the long-term outcome of early intervention has 
so far been elusive and, although a much debated 
treatment strategy, a reluctance to administer powerful 
immunomodulators at onset, in a disease which can 
have a highly variable outcome,7 has made quantiﬁ cation 
of the eﬀ ect of early aggressive immunomodulatory 
treatment on long-term outcome diﬃ  cult. No licensed 
drugs have shown a convincing eﬀ ect on long-term 
disability, or speciﬁ cally on progressive disease.
Although identiﬁ cation of interventions that have a 
signiﬁ cant eﬀ ect in modiﬁ cation of physical disability in 
progressive disease is a main aspiration of clinical trials of 
multiple sclerosis, an obstacle will be the large numbers 
of patients needed to achieve adequate power when 
conventional measures of disability are used. Indeed, this 
challenge might have contributed to negative results in 
trials of progressive disease to date,8 and more accurate 
contemporary power calculations are needed to inform 
future studies that aim to report disability as the primary 
outcome measure. As a result, eﬀ ective alternative 
measures to identify promising drugs in phase 2 studies 
are needed before large-scale investments in larger trials 
are considered.
In multiple sclerosis, measurement of brain atrophy 
has been recognised as a plausible surrogate outcome 
for disability,9,10 and some studies of immunomodulatory 
drugs have shown an eﬀ ect on reducing this outcome. 
Further support for the use of change in brain volume in 
this context has also emerged in an analysis of treatment 
in relapsing multiple sclerosis that showed a correlation 
of treatment eﬀ ect on brain atrophy with the eﬀ ect on 
disability (r²=0·48).11 However, the association with eﬀ ect 
on disability was greater with use of MRI lesion activity 
(r²=0·61) and greater still when both MRI outcomes were 
combined (r²=0·75).11
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In The Lancet, Jeremy Chataway and colleagues12 have 
pursued repurposed drugs with relevant and plausible 
mechanisms of action by studying the eﬀ ects of 
simvastatin 80 mg per day in 140 patients with secondary 
progressive multiple sclerosis in a phase 2, placebo-
controlled randomised trial. This drug was selected for 
its potential anti-inﬂ ammatory and neuroprotective 
properties. Mean annualised atrophy rate was signiﬁ cantly 
lower in patients in the simvastatin group (0·288% 
per year [SD 0·521]) than in those in the placebo group 
(0·584% per year [0·498]) with an adjusted diﬀ erence of 
−0·254% per year (95% CI −0·422 to −0·087; p=0·003); 
a 43% reduction in annualised rate. Furthermore, lower 
disability scores were reported for two of three measures 
after 2 years of simvastatin compared with placebo. 
Although sustained disability was not reported, a 
signiﬁ cant diﬀ erence was noted in favour of simvastatin in 
the mean 2-year Expanded Disability Scale Status (EDSS) 
score (diﬀ erence −0·254, 95% CI −0·464 to −0·069) 
and the Multiple Sclerosis Impact Scale-29 (−4·78, 
−9·39 to −0·02; adjusted for respective baselines). Of 
note, the reported eﬀ ect on these outcomes, presumed 
to be relevant to neurodegenerative processes, was not 
accompanied by signiﬁ cant eﬀ ects on inﬂ ammatory 
outcomes such as relapse, MRI brain lesions, or serum 
immunological markers, which could suggest a 
primary neuroprotective role for simvastatin. Only two 
previous randomised trials (one single-blind)13,14 have 
presented neuroprotective eﬃ  cacy data that seem to be 
independent of anti-inﬂ ammatory eﬀ ects, and both were 
in patients with relapsing-remitting multiple sclerosis.
Chataway and colleagues’ study is a promising and 
novel development. The study is investigator led and 
has therefore focused on clinical need, targeting patients 
with progressive multiple sclerosis in whom most 
disability is incurred. This form of multiple sclerosis has 
been largely neglected by a pharmaceutical industry 
that has so far focused on the early inﬂ ammatory 
processes. A substantial advantage of this study is the 
fairly low cost, availability, and documented safety 
proﬁ le of the drug. The study also reports a predominant 
eﬀ ect on neurodegenerative rather than inﬂ ammatory 
outcomes, suggesting a novel mechanism of action 
that might be suitable as combination treatment with 
immunomodulatory treatments.
Caution in interpretation of these preliminary data 
is, however, needed. Patients with relapsing secondary 
progressive multiple sclerosis were not excluded, which 
might have aﬀ ected results, although frequency of 
relapses was not reduced in the face of a reduction in 
2-year disability. The expected eﬀ ects of simvastin on 
inﬂ ammation were also not shown. Furthermore, the 
disability outcome was a surrogate measure and not 
the usual outcome used in phase 3 trials. This ﬁ nding is 
relevant because single disability measures show great 
variability in the short term,15 and the trial was clearly 
underpowered to identify an eﬀ ect on arguably the least 
sensitive of disability measures (EDSS). The meaning of an 
eﬀ ect on atrophy, without a reduction in lesion activity, 
in predicting the future eﬀ ect on sustained disability 
outcomes is unknown. Further phase 3 studies to 
measure the eﬀ ect of simvastatin on sustained disability, 
particularly in patients with non-relapsing secondary 
progressive and primary progressive multiple sclerosis, are 
clearly needed, but this trial represents a promising point 
from which to develop trials of progressive disease.
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In the SPRING-21 trial, dolutegravir showed non-
inferiority to raltegravir, another integrase inhibitor, 
in antiretroviral-naive adults with HIV-1 infection. 
In the SINGLE trial,2 dolutegravir showed superiority 
over a non-nucleoside reverse transcriptase inhibitor, 
efavirenz. The next obvious step of the dolutegravir 
targeted strategy was to compare dolutegravir with 
a boosted protease inhibitor such as darunavir plus 
ritonavir. The comparison between dolutegravir and 
a boosted protease inhibitor is particularly interesting 
because boosted protease inhibitors are very potent 
and, by contrast with raltegravir and efavirenz,3 
extremely resilien t to HIV resistance development even 
when used as monotherapy.4
In The Lancet, Bonaventura Clotet and colleagues present 
the FLAMINGO study,5 in which 484 antiretroviral-
naive HIV-infected patients were randomly assigned to 
receive two nucleos(t)ide reverse transcriptase inhibitors 
(tenofovir–emtricitabine or abacavir–lamivudine) plus 
either dolutegravir (50 mg) or the boosted protease 
inhibitor darunavir (800 mg) plus ritonavir (100 mg). 
After 48 weeks of follow-up, more than 80% of patients 
in each group achieved virological suppression (217 [90%] 
patients receiving dolutegravir and 200 [83%] patients 
receiving darunavir plus ritonavir had HIV-1 RNA of 
less than 50 copies per mL, adjusted diﬀ erence 7·1% 
[95% CI 0·9–13·2]), and no patient developed drug 
resistance. It is diﬃ  cult to imagine a better outcome for a 
clinical trial in a disease that just two decades ago did not 
have an eﬀ ective treatment.
In a prespeciﬁ ed secondary analysis, dolutegravir 
also showed superiority to darunavir plus ritonavir. The 
data suggest that superiority was driven both by better 
tolerability (nine [3%] patients in the dolutegravir group 
and 20 [9%] patients in the darunavir plus ritonavir 
group discontinued for non-virological reasons) and 
better eﬃ  cacy (virological success in 217 [90%] patients 
in the dolutegravir group vs 200 [83%] patients in 
the darunavir plus ritonavir group), especially in the 
25% of patients who started with viral loads greater 
than 100 000 copies per mL. But is dolutegravir really 
superior to darunavir plus ritonavir? This is a diﬃ  cult 
question to answer for various reasons.
First, FLAMINGO5 is an open-label clinical trial with 
two pills a day taken by patients in the dolutegravir 
group versus four pills a day taken by those in the 
comparator group (darunavir plus ritonavir). The open-
label design might have led to patients, disappointed 
with their treatment assignment, choosing not to 
continue. In fact, six patients withdrew in the darunavir 
plus ritonavir group very early on compared with the 
one patient who withdrew in the dolutegravir group.
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N Treatment emergent resistance
NRTI Integrase NNRTI Protease
ABC/3TC-dolutegravir2 414 0 0 ·· ··
TDF/FTC (or ABC/3TC)-dolutegravir1 411 0 0 ·· ··
TDF/FTC (or ABC/3TC)-dolutegravir5 242 0 0 ·· ··
TDF/FTC/efavirenz2 419 1 ·· 4 ··
TDF/FTC (or ABC/3TC)-raltegravir1 411 4 1 ·· ··
TDF/FTC (or ABC/3TC)-darunavir/r5 242 0 ·· ·· 0
Data are number of patients. TDF=tenofovir. FTC=emtricitabine. ABC=abacavir. 3TC=lamivudine. NRTI=nucleotide 
reverse transcriptase inhibitors. NNRTI=non-nucleotide reverse transcriptase inhibitors.
Table 1: Treatment emergent resistance in phase 3 clinical trials of dolutegravir
